Pharmacologic treatment of childhood hypertension

Pediatric Hypertension: Third Edition

Volumn , Issue , 2013, Pages 539-555

  Ferguson, Michael A ^a   Flynn, Joseph T ^b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

ACE inhibitors; Angiotensin receptor blockers; Beta adrenergic blockers; Calcium channel blockers; Clinical trials; Diuretics; Pharmacotherapy; Vasodilators

Indexed keywords

EID: 84902152273     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-62703-490-6_36     Document Type: Chapter

References (119)

1. Loggie J. Letter: detection of hypertension in childhood. Br Med J. 1973;4(5888):356.
2. Detection of hypertension in childhood. Br Med J. 1973 Sep 15;3(5880):591.
3. Londe S. Blood pressure standards for normal children as determined under office conditions. Clin Pediatr (Phila). 1968;7(7):400-3.
4. Moss AJ, Adams FH. Problems of blood pressure in childhood. Springfield: Charles C. Thomas; 1962.
5. Roberts J, Maurer K. Blood pressure levels of persons 6-74 years. United States, 1971-1974. Vital Health Stat 11. 1977 Sep;(203):i-v, 1-103.
6. Blumenthal S, Epps RP, Heavenrich R, Lauer RM, Lieberman E, Mirkin B, et al. Report of the task force on blood pressure control in children. Pediatrics. 1977 May;59(52 suppl):I-II, 797-820.
7. National high blood pressure education program working group on high blood pressure in children and adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004 Aug;114(2 Suppl 4th Report):555-76.
8. Sinaiko AR, Gomez-Marin O, Prineas RJ. Prevalence of "significant" hypertension in junior high schoolaged children: the Children and Adolescent Blood Pressure Program. J Pediatr. 1989;114(4 Pt 1):664-9.
9. Fixler DE, Laird WP, Fitzgerald V, Stead S, Adams R. Hypertension screening in schools: results of the Dallas study. Pediatrics. 1979;63(1):32-6.
10. Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ. Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics.2004;113(3 Pt 1):475-82.
11. McNiece KL, Poffenbarger TS, Turner JL, Franco KD, Sorof JM, Portman RJ. Prevalence of hypertension and pre-hypertension among adolescents. J Pediatr. 2007;150(6):640e1-44e1.
12. Din-Dzietham R, Liu Y, Bielo MV, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation.2007;116(13):1488-96.
13. Muntner P, He J, Cutler JA, Wildman RP, Whelton PK. Trends in blood pressure among children and adolescents. JAMA. 2004;291(17):2107-13.
14. Boneparth A, Flynn JT. Evaluation and treatment of hypertension in general pediatric practice. Clin Pediatr. 2009;48(1):44-9.
15. Yoon EY, Cohn L, Rocchini A, Kershaw D, Freed G, Ascione F, et al. Antihypertensive prescribing patterns for adolescents with primary hypertension. Pediatrics. 2012;129(1):e1-8.
16. Lurbe E, Cifkova R, Cruickshank JK, Dillon MJ, Ferreira I, Invitti C, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719-42.
17. Hornsby JL, Mongan PF, Taylor AT, Treiber FA. 'White coat' hypertension in children. J Fam Pract.1991;33(6):617-23.
18. Swartz SJ, Srivaths PR, Croix B, Feig DI. Costeffectiveness of ambulatory blood pressure monitoring in the initial evaluation of hypertension in children. Pediatrics. 2008;122(6):1177-81.
19. Sorof JM, Portman RJ. White coat hypertension in children with elevated casual blood pressure. J Pediatr. 2000;137(4):493-7.
20. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903-13.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206-52.
22. Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation. 1998;97(19):1907-11.
23. Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics. 2003;111(1):61-6.
24. Hanevold C, Waller J, Daniels S, Portman R, Sorof J. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics. 2004;113(2):328-33.
25. Wuhl E, Trivelli A, Picca S, Litwin M, Peco-Antic A, Zurowska A, et al. Strict blood-pressure control and progression of renal failure in children. N Engl J Med. 2009;361(17):1639-50.
26. Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr.2006;149(6):746-54.
27. Woroniecki RP, Flynn JT. How are hypertensive children evaluated and managed? A survey of North American pediatric nephrologists. Pediatr Nephrol.2005;20(6):791-7.
28. Blowey DL. Update on the pharmacologic treatment of hypertension in pediatrics. J Clin Hypertens.2012;14(6):383-7.
29. Simonetti GD, Rizzi M, Donadini R, Bianchetti MG. Effects of antihypertensive drugs on blood pressure and proteinuria in childhood. J Hypertens.2007;25(12):2370-6.
30. Prichard BN, Cruickshank JM, Graham BR. Betaadrenergic blocking drugs in the treatment of hypertension. Blood Press. 2001;10(5-6):366-86.
31. Bullo M, Tschumi S, Bucher BS, Bianchetti MG, Simonetti GD. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012;60(2):444-50.
32. Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation. 1998;97(14):1411-20.
33. Meyers RS, Siu A. Pharmacotherapy review of chronic pediatric hypertension. Clin Ther. 2011; 33(10):1331-56.
34. DiBianco R. Angiotensin converting enzyme inhibition. Unique and effective therapy for hypertension and congestive heart failure. Postgrad Med.1985;78(5):229-41. 44, 47-8.
35. Smith CG, Vane JR. The discovery of captopril. FASEB J. 2003;17(8):788-9.
36. Oberfield SE, Case DB, Levine LS, Rapaport R, Rauh W, New MI. Use of the oral angiotensin I-converting enzyme inhibitor (captopril) in childhood malignant hypertension. J Pediatr. 1979;95(4):641-4.
37. Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension:report of the International Collaborative Study Group. Pediatrics. 1985;75(6):1091-100.
38. United States Food and Drug Administration. Summary of medical and clinical pharmacology reviews. [updated 2008 Jan 15]. Available from http://www.fda.gov/downloads/Drugs/Development ApprovalProcess/DevelopmentResources/UCM 162982.pdf . Accessed 15 Aug 2012.
39. Sinaiko AR, Kashtan CE, Mirkin BL. Antihypertensive drug therapy with captopril inchildren and adolescents. Clin Exp Hypertens A.1986;8(4-5):829-39.
40. Sinaiko AR, Mirkin BL, Hendrick DA, Green TP, O'Dea RF. Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease. J Pediatr. 1983;103(5):799-805.
41. Tack ED, Perlman JM. Renal failure in sick hypertensive premature infants receiving captopril therapy. J Pediatr. 1988;112(5):805-10.
42. Wells T, Frame V, Soffer B, Shaw W, Zhang Z, Herrera P, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol. 2002;42(8):870-80.
43. Soffer B, Zhang Z, Miller K, Vogt BA, Shahinfar S. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens.2003;16(10):795-800.
44. United States Food and Drug Administration. New pediatric labeling information database [updated 2012 July 24]; Available from http://www.accessdata. fda.gov/scripts/sda/sdNavigation.cfm? sd=labelingdatabase. Accessed 15 Aug 2012.
45. Li JS, Berezny K, Kilaru R, Hazan L, Portman R, Hogg R, et al. Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children? Hypertension. 2004;44(3):289-93.
46. Menon S, Berezny KY, Kilaru R, Benjamin Jr DK, Kay JD, Hazan L, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J. 2006;152(2):394-9.
47. Brewster LM, van Montfrans GA, Kleijnen J. Systematic review: antihypertensive drug therapy in black patients. Ann Intern Med. 2004;141(8):614-27.
48. United States Food and Drug Administration. Summaries of medical and clinical pharmacology reviews. Available from www.fda.gov/downloads/ Drugs/DevelopmentApprovalProcess/Development Resources/UCM161981.pdf . Accessed 15 Aug 2012.
49. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008;121(8):656-63.
50. Shahinfar S, Cano F, Soffer BA, Ahmed T, Santoro EP, Zhang Z, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens. 2005;18(2 Pt 1):183-90.
51. United States National Institutes of Health. Study of losartan in pediatric patients with hypertension. [updated 2012 June 8]. Available from http://www. clinicaltrials.gov/ct2/show/NCT00756938 . Accessed 15 Aug 2012.
52. Trachtman H, Hainer JW, Sugg J, Teng R, Sorof JM, Radcliffe J. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens. 2008;10(10):743-50.
53. Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, et al. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age. J Hypertens. 2010;28(5):1083-90.
54. Tullus K. Safety concerns of angiotensin II receptor blockers in preschool children. Arch Dis Child.2011;96(9):881-2.
55. Hazan L, Hernandez Rodriguez OA, Bhorat AE, Miyazaki K, Tao B, Heyrman R. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension. 2010;55(6):1323-30.
56. Sakarcan A, Tenney F, Wilson JT, Stewart JJ, Adcock KG, Wells TG, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol. 2001;41(7):742-9.
57. Franscini LM, Von Vigier RO, Pfister R, Casaulta-Aebischer C, Fossali E, Bianchetti MG. Effectiveness and safety of the angiotensin II antagonist irbesartan in children with chronic kidney diseases. Am J Hypertens. 2002;15(12):1057-63.
58. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47(3):312-8.
59. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709-17.
60. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med.2003;348(14):1309-21.
61. Buck ML. Clinical experience with spironolactone in pediatrics. Ann Pharmacother. 2005;39(5):823-8.
62. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH. Aldosterone-receptor antagonism in hypertension. J Hypertens. 2009;27(4):680-91.
63. Struthers A, Krum H, Williams GH. A comparison of the aldosterone-blocking agents eplerenone and spironolactone. Clin Cardiol. 2008;31(4):153-8.
64. Li JS, Flynn JT, Portman R, Davis I, Ogawa M, Shi H, et al. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension:a randomized, double-blind, dose-response study. J Pediatr. 2010;157(2):282-7.
65. Kaplan NM, Victor RG. Clinical hypertension. 10th ed. New York: Lippincott Williams and Wilkins; 2010.
66. Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens. 2009;11(7):369-75.
67. Batisky DL, Sorof JM, Sugg J, Llewellyn M, Klibaner M, Hainer JW, et al. Efficacy and safety of extended release metoprolol succinate in hypertensive children 6 to 16 years of age: a clinical trial experience. J Pediatr. 2007;150(2):134-9. 9.e1.
68. Sorof JM, Cargo P, Graepel J, Humphrey D, King E, Rolf C, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomizeddouble-blind, placebo-controlled trial. Pediatr Nephrol. 2002;17(5):345-50.
69. Robinson RF, Nahata MC, Batisky DL, Mahan JD. Pharmacologic treatment of chronic pediatric hypertension. Paediatr Drugs. 2005;7(1):27-40.
70. Griswold WR, McNeal R, Mendoza SA, Sellers BB, Higgins S. Propranolol as an antihypertensive agent in children. Arch Dis Child. 1978;53(7):594-6.
71. Bachmann H. Propranolol versus chlorthalidone-a prospective therapeutic trial in children with chronic hypertension. Helv Paediatr Acta. 1984;39(1):55-61.
72. Friedman DB, Musch TI, Williams RS, Ordway GA. Beta adrenergic blockade with propranolol and atenolol in the exercising dog: evidence for beta 2 adrenoceptors in the sinoatrial node. Cardiovasc Res.1987;21(2):124-9.
73. Pedersen ME, Cockcroft JR. The vasodilatory betablockers. Curr Hypertens Rep. 2007;9(4):269-77.
74. Dilmen U, Caglar MK, Senses DA, Kinik E. Nifedipine in hypertensive emergencies of children. Am J Dis Child. 1983;137(12):1162-5.
75. Evans JH, Shaw NJ, Brocklebank JT. Sublingual nifedipine in acute severe hypertension. Arch Dis Child. 1988;63(8):975-7.
76. Roth B, Herkenrath P, Krebber J, Abu-Chaaban M. Nifedipine in hypertensive crises of infants and children. Clin Exp Hypertens A. 1986;8(4-5):871-7.
77. Siegler RL, Brewer ED. Effect of sublingual or oral nifedipine in the treatment of hypertension. J Pediatr.1988;112(5):811-3.
78. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA. 1996;276(16):1328-31.
79. Egger DW, Deming DD, Hamada N, Perkin RM, Sahney S. Evaluation of the safety of short-acting nifedipine in children with hypertension. Pediatr Nephrol. 2002;17(1):35-40.
80. Blaszak RT, Savage JA, Ellis EN. The use of shortacting nifedipine in pediatric patients with hypertension. J Pediatr. 2001;139(1):34-7.
81. Truttmann AC, Zehnder-Schlapbach S, Bianchetti MG. A moratorium should be placed on the use of short-acting nifedipine for hypertensive crises. Pediatr Nephrol. 1998;12(3):259.
82. Flynn JT. Nifedipine in the treatment of hypertension in children. J Pediatr. 2002;140(6):787-8.
83. Silverstein DM, Palmer J, Baluarte HJ, Brass C, Conley SB, Polinsky MS. Use of calcium-channel blockers in pediatric renal transplant recipients. Pediatr Transplant. 1999;3(4):288-92.
84. Sahney S. A review of calcium channel antagonists in the treatment of pediatric hypertension. Paediatr Drugs. 2006;8(6):357-73.
85. Flynn JT, Warnick SJ. Isradipine treatment of hypertension in children: a single-center experience. Pediatr Nephrol. 2002;17(9):748-53.
86. Strauser LM, Groshong T, Tobias JD. Initial experience with isradipine for the treatment of hypertension in children. South Med J. 2000;93(3):287-93.
87. Johnson CE, Jacobson PA, Song MH. Isradipine therapy in hypertensive pediatric patients. Ann Pharmacother. 1997;31(6):704-7.
88. Miyashita Y, Peterson D, Rees JM, Flynn JT. Isradipine for treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens. 2010;12(11):850-5.
89. Blowey DI, Moncica I, Scolnik D, Arbus GS, Hebert D, Balfe JW, et al. The pharmacokinetics of extended release felodipine in children. Eur J Clin Pharmacol.1996;50(1-2):147-8.
90. Moncica I, Oh PI, ul Qamar I, Scolnik D, Arbus GS, D H. A crossover comparison of extended release felodipine with prolonged action nifedipine in hypertension. Arch Dis Child. 1995;73(2):154-6.
91. Trachtman H, Frank R, Mahan JD, Portman R, Restaino I, Matoo TK, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol. 2003;18(6):548-53.
92. Tallian KB, Nahata MC, Turman MA, Mahan JD, Hayes JR, Mentser MI. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol. 1999;13(4):304-10.
93. Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens. 2000;13(10):1061-6.
94. Rogan JW, Lyszkiewicz DA, Blowey D, Khattak S, Arbus GS, Koren G. A randomized prospective crossover trial of amlodipine in pediatric hypertension. Pediatr Nephrol. 2000;14(12):1083-7.
95. von Vigier RO, Franscini LM, Bianda ND, Pfister R, Casaulta Aebischer C, Bianchetti MG. Antihypertensive efficacy of amlodipine in children with chronic kidney diseases. J Hum Hypertens.2001;15(6):387-91.
96. Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. Am J Ther. 2006;13(3):198-204.
97. Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol. 2005;20(5):631-5.
98. Flynn JT, Nahata MC, Mahan Jr JD, Portman RJ. Population pharmacokinetics of amlodipine in hypertensive children and adolescents. J Clin Pharmacol. 2006;46(8):905-16.
99. Flynn JT, Newburger JW, Daniels SR, Sanders SP, Portman RJ, Hogg RJ, et al. A randomized, placebocontrolled trial of amlodipine in children with hypertension. J Pediatr. 2004;145(3):353-9.
100. Lyszkiewicz DA, Levichek Z, Kozer E, Yagev Y, Moretti M, Hard M, et al. Bioavailability of a pediatric amlodipine suspension. Pediatr Nephrol. 2003; 18(7):675-8.
101. Nahata MC, Morosco RS, Hipple TF. Stability of amlodipine besylate in two liquid dosage forms. J Am Pharm Assoc. 1999;39(3):375-7.
102. Sinaiko AR, Mirkin BL. Management of severe childhood hypertension with minoxidil: a controlled clinical study. J Pediatr. 1977;91(1):138-42.
103. Puri HC, Maltz HE, Kaiser BA, Potter DE. Severe hypertension in children with renal disease: treatment with minoxidil. Am J Kidney Dis. 1983;3(1):71-5.
104. Strife CF, Quinlan M, Waldo FB, Fryer CJ, Jackson EC, Welch TR, et al. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics. 1986;78(5):861-5.
105. Falkner B, Onesti G, Lowenthal DT, Affrime MB. The use of clonidine monotherapy in adolescent hypertension. Chest. 1983;83(2 Suppl):425-7.
106. Garovic V, Textor SC. Renovascular hypertension:current concepts. Semin Nephrol. 2005;25(4):261-71.
107. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation. 2005;112(9):1362-74.
108. Flynn JT, Pierce CB, Miller 3rd ER, Charleston J, Samuels JA, Kupferman J, et al. Reliability of resting blood pressure measurement and classification using an oscillometric device in children with chronic kidney disease. J Pediatr. 2012;160(3):434e1-40e1.
109. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and endstage renal disease in men. N Engl J Med. 1996; 334(1):13-8.
110. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63(4):1468-74.
111. Locatelli F, Marcelli D, Comelli M, Alberti D, Graziani G, Buccianti G, et al. Proteinuria and blood pressure as causal components of progression to end-stage renal failure. Northern Italian Cooperative Study Group. Nephrol Dial Transplant. 1996;11(3):461-7.
112. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensinconverting- enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med. 1996;334(15):939-45.
113. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebocontrolled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non- diabetic nephropathy. Lancet. 1997 Jun 28;349(9069):1857-63.
114. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med. 2001;135(2):73-87.
115. Laragh JH, Sealey JE. The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to longterm blood pressure. Am J Hypertens. 2011;24(11):1164-80.
116. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens. 2001;14(9 Pt 1):837-54.
117. Egan BM, Basile JN, Rehman SU, Davis PB, Grob 3rd CH, Riehle JF, et al. Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial. Am J Hypertens. 2009;22(7):792-801.
118. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, et al. Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens. 2010;23(9):1014-22.
119. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Pressor responses to antihypertensive drug types. Am J Hypertens. 2010;23(9):1031-7.